Table 4.
Association of ACEi/ARB discontinuation with 28-day mortality in ACEi/ARB users
| Model | Recipients of Kidney Transplant (n=160) | Patients on Dialysis (n=188) | ||||
|---|---|---|---|---|---|---|
| Continuers | Discontinuers | P Value | Continuers | Discontinuers | P Value | |
| Event rate (events)a | 5.8 (55) | 4.9 (33) | 7.2 (184) | 6.0 (60) | ||
| Model 1b | Reference | 3.05 (1.40 to 6.62) | 0.005 | Reference | 1.16 (0.64 to 2.08) | 0.63 |
| Model 2c | Reference | 4.48 (1.87 to 10.71) | 0.001 | Reference | 1.41 (0.69 to 2.88) | 0.34 |
| Model 3d | Reference | 5.23 (1.99 to 13.73) | 0.001 | Reference | 1.68 (0.77 to 3.66) | 0.19 |
| Model 4e | Reference | 5.03 (1.84 to 13.76) | 0.002 | Reference | 2.01 (0.91 to 4.45) | 0.09 |
| Model 5f | Reference | 1.36 (0.40 to 4.58) | 0.62 | Reference | 1.52 (0.51 to 4.56) | 0.45 |
Presented are the hazard ratios (95% confidence intervals) in transplant recipients and patients on dialysis, separately, unless otherwise indicated. ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.
a
Event rate per 100 person-weeks.
b
Model 1, crude.
c
Model 2, model 1 plus age, sex, and frailty.
d
Model 3, model 2 plus systolic BP, diabetes, and heart failure.
e
Model 4, model 3 plus start of anti-inflammatory therapy and antiviral therapy.
f
Model 5, model 4 plus cough, shortness of breath, fever, pulse rate, respiration rate, lymphocyte count, C-reactive protein, and >25% serum creatinine increase (only in transplant population).